DaVita (DVA)
(Delayed Data from NYSE)
$137.72 USD
+1.77 (1.30%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $137.80 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$137.72 USD
+1.77 (1.30%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $137.80 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
DaVita HealthCare (DVA) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks.com featured highlights include: Brinker International, Target, DaVita, TRI Pointe Group and PennyMac Financial Services
by Zacks Equity Research
Zacks.com featured highlights include: Brinker International, Target, DaVita, TRI Pointe Group and PennyMac Financial Services
Buy 4 Beaten-Down MedTech Value Stocks Amid September Selloffs
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks which have been battered by the pandemic-led market meltdown and can be considered for long-term gains.
5 Stocks Near 52-Week Highs That are Poised to Scale Higher
by Anirudha Bhagat
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have higher chances of carrying the momentum ahead.
The Zacks Analyst Blog Highlights: AZN, SFM, DVA, BIG and RCII
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AZN, SFM, DVA, BIG and RCII
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.
4 Stock-Picking Strategies as Tech Rout Roils Market
by Sweta Killa
We have highlighted some stock-picking ideas from the top-ranked cohort that could prove extremely beneficial for investors in the current market environment, reducing the risk of a downside.
Want to Bet on Relative Price Strength? Try These 5 Stocks
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
The Zacks Analyst Blog Highlights: JPM, DVA, UAL, GPI and GPK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPM, DVA, UAL, GPI and GPK
Should Value Investors Buy DaVita HealthCare (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
What September Lull? Buy Laggards Instead of Tech Leaders
by Sanghamitra Saha
The S&P 500 posted its worst single-session drop in nearly three months mainly on profit booking. While high-flying tech names were hurt the most, laggards are better positioned.
3 Top Outpatient and Home Healthcare Stocks to Watch Out For
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, rising dependence on telehealth and AI's dominant role should drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, USPH and PNTG are well positioned to gain from the prospects.
Raise a Toast to Buffett's 90th Birthday With These 2 Stocks
by Tirthankar Chakraborty
In honor of Buffett's 90th birthday, we have highlighted two of his top holdings that are worth buying.
DaVita HealthCare (DVA) Down 4.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is DaVita HealthCare (DVA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Buy Stocks For August 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
5 PEG-Driven Value Stocks to Invest in Coronavirus-Hit Market
by Urmimala Biswas
PEG ratio is complicated, considering the limitations in calculating the future earnings growth potential of a stock.
The Zacks Analyst Blog Highlights: Best Buy, Activision Blizzard, DaVita, Micron and PulteGroup
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Best Buy, Activision Blizzard, DaVita, Micron and PulteGroup
5 Top Stocks to Buy as S&P 500 Nears an All-Time High
by Tirthankar Chakraborty
Given that the S&P 500 is close to its first record close in six months as hopes rise for economic stimulus and a COVID-19 vaccine, investing in some of the top stocks listed in the index seems wise.
6 Stocks Trading Near 52-Week Highs That Can Rally Further
by Anirudha Bhagat
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have higher chances of carrying the momentum forward.
The Zacks Analyst Blog Highlights: DaVita, PayPal, Century Communities, Berry Global and Turning Point Brands
by Tirthankar Chakraborty
The Zacks Analyst Blog Highlights: DaVita, PayPal, Century Communities, Berry Global and Turning Point Brands
Buy These 5 Stocks Before It's Too Late
by Sejuti Banerjea
With solid earnings beats and upward revisions in estimates, these stocks are worth adding to your portfolio.
New Strong Buy Stocks For August 5th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: